Innovus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of gene therapies for inherited retinal diseases and other ocular disorders. Leveraging adeno-associated virus (AAV) vector technology, Innovus is advancing a pipeline of product candidates designed to address underlying genetic causes of vision loss. The company’s primary objective is to translate scientific breakthroughs in ophthalmic gene therapy into meaningful treatments for patients with limited or no therapeutic options.
The company’s lead programs include treatments for conditions such as retinitis pigmentosa, Stargardt disease and achromatopsia, each employing proprietary AAV-based delivery methods to introduce functional copies of disease-related genes into retinal cells. Innovus utilizes a versatile platform that supports both intravitreal and subretinal administration, enabling targeted delivery to specific regions of the eye. Preclinical data have demonstrated sustained transgene expression and favorable safety profiles, setting the stage for upcoming regulatory filings and early-phase clinical trials.
Innovus collaborates with academic institutions and specialized contract research organizations in North America and Europe to optimize vector design, manufacturing processes and preclinical study protocols. These partnerships bolster the company’s in-house development capabilities and streamline the path from proof-of-concept studies to clinical proof of safety and efficacy. Headquartered in Cleveland, Ohio, Innovus maintains a global perspective on rare ocular disease markets and actively explores strategic alliances for future commercialization.
Founded through a strategic combination of gene therapy innovators and seasoned pharmaceutical executives, Innovus Pharmaceuticals has assembled leadership with deep expertise in ophthalmology, viral vector biology and regulatory affairs. The management team’s collective experience and the company’s robust intellectual property estate underpin its mission to bring durable, vision-restoring therapies to patients worldwide. As Innovus advances its clinical pipeline, it remains committed to addressing the unmet medical needs of individuals affected by hereditary vision disorders.
AI Generated. May Contain Errors.
Free INNVD Stock Alerts